OBJECTIVE: To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor (G-CSF) in breast cancer patients. METHODS: A total of 57 breast cancer patients were treated with docetaxel 120 mg/m(2). When the white blood cell (WBC) count decreased to 1.0×10(9)/L, patients were given G-CSF 5 μg/kg daily by subcutaneous injection until the end of apheresis. Peripheral blood mononuclear cells (MNC) were isolated by Cobe Spectra Apheresis System. The percentage of CD34(+) cell was assayed by flow cytometry. RESULTS: At a median 6 of days (range 3-8) after the administration of docetaxel, the median WBC count decreased to 1.08×10(9)/L (range 0.20-2.31). The median duration of G-CSF mobilization was 3 days (range 2-7). The MNC collection was conducted 8-12 days (median 10 days) after docetaxel treatment. The median MNC was 5.35×10(8)/kg (range 0.59-14.07), the median CD34(+) cell count was 2.43×10(6)/kg (range 0.16-16.69). The CD34(+) cell count was higher than 1.00×10(6)/kg in 47 of 57 cases (82.46%) and higher than 2.00×10(6)/kg in 36 cases (63.16%). The CD34(+) cell count was higher than 2.00×10(6)/kg in 27 collections (23.68%). The MNC count and the CD34(+) cell count were correlated with the bottom of WBC after docetaxel chemotherapy (r=0.364, 0.502, P=0.005, 0.000). The CD34(+) cell count was correlated with the MNC count (r=0.597, P=0.000). The mobilization and apheresis were well tolerated in all patients. Mild perioral numbness and numbness of hand or feet were observed in 3 cases. No serious adverse events were reported. CONCLUSION: Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.
OBJECTIVE: To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor (G-CSF) in breast cancerpatients. METHODS: A total of 57 breast cancerpatients were treated with docetaxel 120 mg/m(2). When the white blood cell (WBC) count decreased to 1.0×10(9)/L, patients were given G-CSF 5 μg/kg daily by subcutaneous injection until the end of apheresis. Peripheral blood mononuclear cells (MNC) were isolated by Cobe Spectra Apheresis System. The percentage of CD34(+) cell was assayed by flow cytometry. RESULTS: At a median 6 of days (range 3-8) after the administration of docetaxel, the median WBC count decreased to 1.08×10(9)/L (range 0.20-2.31). The median duration of G-CSF mobilization was 3 days (range 2-7). The MNC collection was conducted 8-12 days (median 10 days) after docetaxel treatment. The median MNC was 5.35×10(8)/kg (range 0.59-14.07), the median CD34(+) cell count was 2.43×10(6)/kg (range 0.16-16.69). The CD34(+) cell count was higher than 1.00×10(6)/kg in 47 of 57 cases (82.46%) and higher than 2.00×10(6)/kg in 36 cases (63.16%). The CD34(+) cell count was higher than 2.00×10(6)/kg in 27 collections (23.68%). The MNC count and the CD34(+) cell count were correlated with the bottom of WBC after docetaxel chemotherapy (r=0.364, 0.502, P=0.005, 0.000). The CD34(+) cell count was correlated with the MNC count (r=0.597, P=0.000). The mobilization and apheresis were well tolerated in all patients. Mild perioral numbness and numbness of hand or feet were observed in 3 cases. No serious adverse events were reported. CONCLUSION: Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancerpatients.
Authors: G G Laport; G F Fleming; S Waggoner; T M Zimmerman; D L Grinblatt; S F Williams Journal: Bone Marrow Transplant Date: 2001-04 Impact factor: 5.483
Authors: J Gómez-Espuch; J M Moraleda; F Ortuño; M L Lozano; F Ayala; C Vallejo; F de Arriba; V Vicente Journal: Bone Marrow Transplant Date: 2000-02 Impact factor: 5.483
Authors: Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-02-13 Impact factor: 44.544
Authors: H M Prince; G C Toner; J F Seymour; D Blakey; P Gates; S Eerhard; P Chapple; D Wall; M Quinn; S Juneja; M Wolf; E H Januszewicz; G Richardson; J Scarlett; P Briggs; M Brettell; D Rischin Journal: Bone Marrow Transplant Date: 2000-09 Impact factor: 5.483
Authors: A R Zander; C Schmoor; N Kröger; W Krüger; V Möbus; N Frickhofen; B Metzner; W E Berdel; M Koenigsmann; E Thiel; H Wandt; K Possinger; R Kreienberg; M Schumacher; W Jonat Journal: Ann Oncol Date: 2008-02-27 Impact factor: 32.976
Authors: Joyce O'Shaughnessy; David Miles; Svetislava Vukelja; Vladimir Moiseyenko; Jean-Pierre Ayoub; Guadalupe Cervantes; Pierre Fumoleau; Stephen Jones; Wing-Yiu Lui; Louis Mauriac; Chris Twelves; Guy Van Hazel; Shailendra Verma; Robert Leonard Journal: J Clin Oncol Date: 2002-06-15 Impact factor: 44.544
Authors: X Wang; J Ren; J Zhang; Y Yan; N Jiang; J Yu; L Di; G Song; L Che; J Jia; X Zhou; H Yang; H K Lyerly Journal: Clin Transl Oncol Date: 2015-08-13 Impact factor: 3.405